Journal
JOURNAL OF IMMUNOLOGY
Volume 175, Issue 4, Pages 2061-2065Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.175.4.2061
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL66533, HL56399] Funding Source: Medline
- NIAID NIH HHS [5T32-AI07077-04, AI50180, AI56352] Funding Source: Medline
- NIDCD NIH HHS [5T32-DC00058] Funding Source: Medline
Ask authors/readers for more resources
The establishment of ICOS as an important regulator of Th2 development and effector function makes the ICOS locus an attractive candidate for Th2-mediated diseases, such as asthma and allergy. In evaluation of this candidate locus in humans, we identified 11 variants and determined that two in the putative promoter region are significantly associated with allergic sensitization and serum IgE levels. In addition, cultures of activated PBMCs from individuals homozygous for the associated polymorphisms produced increased levels of the Th2 cytokines, IL-4, IL-5, and IL-13, as well as TNF-alpha compared with controls. One of the polymorphisms, -1413G/A, demonstrated differential NF-kappa B binding in mobility shift analysis, suggesting that this polymorphism has functional consequences. Overall, these data demonstrate that ICOS is a susceptibility gene for allergic sensitization, perhaps through the promotion of Th2 differentiation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available